Three-year outcomes of glucagon-like peptide-1 agonists in atrial fibrillation with sarcoidosis and diabetes

Heart Rhythm. 2025 May 8:S1547-5271(25)02419-1. doi: 10.1016/j.hrthm.2025.04.067. Online ahead of print.

¹ Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona. Electronic address: tan.minchoon@mayo.edu.
² Department of Medicine, Cleveland Clinic Fairview Hospital, Cleveland, Ohio.
³ Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
⁴ Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
⁵ Department of Cardiovascular Medicine, Cooper University Hospital, Camden, New Jersey.
⁶ Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
⁷ Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona.

No abstract available

Keywords: Atrial fibrillation; GLP-1 agonist; Long-term outcomes; Mortality; Population-based study; Sarcoidosis.